One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp–derived measures of β-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). β-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09–2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: −0.8 ± 0.1 and −0.7 ± 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference −4.6 kg, P < 0.0001). β-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves β-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, β-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Obviously, patients treated with exenatide showed a greater improvement in acute -cell function, which is considered to be the result of binding to the -cell GLP-1 receptor (13).”
BackgroundResultKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 2×
“3 ype 2 diabetes mellitus is characterized by beta-cell dysfunction against a background of obesity-related insulin resistance (1).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies also showed amelioration of surrogate measures of beta-cell function (4-6; 8).”
BackgroundResultInfluentialBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“This protective effect has its onset within 24 h (86) and persists as long as GLP-1 therapy is continued (84,85,93).”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“When on treatment, the achieved weight loss with GLP-1RA persisted over 52 weeks (Nauck et al. 2007, Bunck et al. 2009, Garber et al. 2009) and in open-label extension trials up to 2–3 years (Bunck et al. 2011, Garber et al. 2011, Macconell et al. 2013).”
Self-citationRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
“…and IGT subjects - Uncertain effect on -cell mass in humans - Uncertain long-term beneficial effect function in diabetic animals and T2D patients (Bunck et al., 2009; Greig et al., 1999; Mu et al., 2006; Mu et al., 2009; Scherbaum et al., 2008; Young et al., 1999) IL-1Ra (Anakinra) -…”
BackgroundAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
“Similar to the study mentioned above for exenatide [132], during a standard hyperglycemic clamp procedure with a later arginine-stimulation test, LIRA improved first- and second-phase insulin response by 118% and 79%, respectively, versus placebo (P<0.”
BackgroundResultSelf-citationHeise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 251
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
“We previously showed that EXE, as compared with insulin glargine (GLAR), improved pancreatic b-cell secretory function against a background of similar glycemic control (7).”
BackgroundMethodResultInfluentialSelf-citationEdridge, C. L., Dunkley, A. J., Bodicoat, D. H., Rose, T. C., Gray, L. J., Davies, M. J., & Khunti, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126427 · Cited by 225
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
van der Zijl, N. J., Goossens, G. H., Moors, C. C. M., van Raalte, D. H., Muskiet, M. H. A., Pouwels, P. J. W., Blaak, E. E., & Diamant, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1722 · Cited by 198
Self-citationMatthews, D. R., Dejager, S., Ahren, B., Fonseca, V., Ferrannini, E., Couturier, A., Foley, J. E., & Zinman, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01233.x · Cited by 199
Del Prato, S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 197
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
“A study of T2DM patients on metformin found that 4-week treatment cessation from the GLP-1 agonist exenatide following one year of combination metformin þ exenatide therapy led to a massive decline in b-cell function back to pretreatment levels [244] that was comparable although slightly mitigated if treatment cessati…”
BackgroundBeta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Liu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 169
“amide] or GLP-1 [7-37]), thus leading to”
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161
“5%) and baseline values of corresponding outcome measure as a covariate (5).”
BackgroundInfluentialSelf-citationDiamant, M., van Gaal, L., Guerci, B., Stranks, S., Han, J., Malloy, J., Boardman, M. K., & Trautmann, M. (2014) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(14)70029-4 · Cited by 163
Self-citationLiu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 148
van Raalte, D. H., van Genugten, R. E., Linssen, M. M. L., Ouwens, D. M., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc10-1677 · Cited by 150
Self-citationType 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
“(49) in type 2 diabetes strongly argues against an effect of GLP-1 to increase b-cell mass in humans, since discontinuation of exenatide for 1 month was associated with return of b-cell function to pretreatment levels.”
BackgroundBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 142
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
Katout, M., Zhu, H., Rutsky, J., Shah, P., Brook, R. D., Zhong, J., & Rajagopalan, S. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpt196 · Cited by 140
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
“The tendency of lower TG levels in the patients compared with control subjects is probably the result of exogenous insulin (52).”
BackgroundRetnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 158
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132
Self-citationMcIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · PubMed Central · Cited by 155
Exenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125
In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide
Menzel, C., Holzeisen, T., Laffleur, F., Zaichik, S., Abdulkarim, M., Gumbleton, M., & Bernkop‐Schnürch, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.018 · Cited by 132
“This 39-amino acid, glucogon-like peptide-1 glucagon-like peptide-1 agonist increases insulin secretion, suppresses pancreatic glucagon release and slows down gastric emptying [3].”
BackgroundSchopman, J. E., Simon, A. C. R., Hoefnagel, S. J. M., Hoekstra, J. B. L., Scholten, R. J. P. M., & Holleman, F. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2470 · Cited by 120
“Too few studies had insulin as comparator, so these could not be meta-analysed [28-30] (Table 1, Table 2).”
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
Foley (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10952 · Cited by 119
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
Self-citationMonami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112
“[37]”
Solomon, T. P. J., Haus, J. M., Kelly, K. R., Rocco, M., Kashyap, S. R., & Kirwan, J. P. (2010) · Diabetes Care · doi:10.2337/dc09-2021 · Cited by 113
“In recent years, surgical techniques and exenatide compounds have emerged (13) and received attention for their potential to initiate insulin secretion in severely obese diabetic patients.”
BackgroundBunck, M. C., Eliasson, B., Cornér, A., Heine, R. J., Shaginian, R. M., Taskinen, M. ‐., Yki‐Järvinen, H., Smith, U., & Diamant, M. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01355.x · Cited by 110
Self-citationTargeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104
Speck, M., Cho, Y. M., Asadi, A., Rubino, F., & Kieffer, T. J. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00422.2010 · Cited by 108
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
“The RCT conducted by Bunck et al.20 included 5 different doses of exenatide: 10 μg BID (62.1% of participants), 15 μg BID (3.4%), 10 μg 3 times daily (TID) (6.9%), 15 μg TID (3.4”
MethodInfluentialThe RISE Consortium (2014) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 100
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Monami, M., Dicembrini, I., Marchionni, N., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/672658 · Cited by 99
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
“Beta cell function was significantly improved with exenatide compared with insulin glargine over 1 year, but returned to pre-treatment values 4 weeks after treatment cessation [74].”
BackgroundClarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 100
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P., & Waugh, N. R. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-20 · Cited by 88
Inagaki, N., Atsumi, Y., Oura, T., Saito, H., & Imaoka, T. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.07.007 · Cited by 93
Nediani, C., Raimondi, L., Borchi, E., & Cerbai, E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3198 · Cited by 88
Umpierrez, G. E., Blevins, T., Rosenstock, J., Cheng, C., Anderson, J. H., Bastyr, E. J., & for the EGO Study Group (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01366.x · Cited by 84
Effects of glucocorticoids and exercise on pancreatic β‐cell function and diabetes development
Beaudry, J. L., & Riddell, M. C. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2310 · Cited by 84
Nreu, B., Dicembrini, I., Tinti, F., Sesti, G., Mannucci, E., & Monami, M. (2020) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.013 · Cited by 84
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83
“The combined glucose and arginine-stimulated C-peptide secretion rate is the established measure of beta cell capacity to secrete insulin [2, 9].”
BackgroundMethodResultSelf-citationGlucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?
van Raalte, D. H., & Diamant, M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70012-2 · Cited by 99
Self-citationEvolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Rajan, S., Dickson, L. M., Mathew, E., Orr, C. M. O., Ellenbroek, J. H., Philipson, L. H., & Wicksteed, B. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.010 · Cited by 77
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 81
Recent advances in incretin‐based therapies
Russell-Jones, D. L., & Gough, S. C. L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04483.x · Cited by 82
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126003 · Cited by 70
Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
Buysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68
Tzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73
Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 73
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
Derosa, G., Carbone, A., Franzetti, I., Querci, F., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.022 · Cited by 77
Dailey, G. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.025 · Cited by 66
Scott, D., Boye, K., Timlin, L., Clark, J., & Best, J. (2013) · Diabetes, obesity and metabolism · doi:10.1111/dom.12007 · Cited by 59
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Miras, A. D., & le Roux, C. W. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.205 · Cited by 64
NREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
Arakawa, M., Ebato, C., Mita, T., Hirose, T., Kawamori, R., Fujitani, Y., & Watada, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.054 · Cited by 65
Simental‐Mendía, L. E., Sánchez‐García, A., Linden‐Torres, E., & Simental‐Mendía, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14855 · Cited by 59
Gurney, K., MacConell, L., Brown, C., & Han, J. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s28387 · Cited by 61
“26, 34 Studies of the GLP-1 GLP-1 receptor agonist 48 In 2007 and 2008, the US Food and Drug Administration issued a safety alert and update based on postmarketing surveillance that reported a total of 36 cases of acute pancreatitis in patients treated with exenatide.”
Goals of Treatment for Type 2 Diabetes
Marchetti, P., Lupi, R., Guerra, S. D., Bugliani, M., D’Aleo, V., Occhipinti, M., Boggi, U., Marselli, L., & Masini, M. (2009) · Diabetes Care · doi:10.2337/dc09-s306 · Cited by 70
“In this study, glucose values were significantly associated with -cell function (36).”
BackgroundMethodDalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
Metadata
- Authors
- Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Heine, R. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Department of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg, Sweden;
- Amylin Pharmaceuticals, San Diego, California;
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;
- Eli Lilly (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-05
- Volume
- 32
- Issue
- 5
- Pages
- 762-768
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2671094
- OpenAlex
- W2148798434
- Cited by
- 388
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 16 · 2016: 19 · 2015: 24 · 2014: 34 · 2013: 40 · 2012: 44
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, beta-cell function, metformin, glycemic control, HbA1c, body weight, C-peptide secretion, drug discontinuation, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Insulin Secretion, Arginine, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Kinetics, Male, Metformin, Middle Aged, Peptides, Venoms, Body Mass Index, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.